MGD 006

Drug Profile

MGD 006

Alternative Names: CD123 x CD3; MGD-006; S 80880

Latest Information Update: 06 Jan 2017

Price : $50

At a glance

  • Originator MacroGenics
  • Developer MacroGenics; Servier
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Immunomodulators; Interleukin-3-receptor-alpha-subunit-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 05 Jan 2017 MGD 006 receives Orphan Drug status for Acute myeloid leukaemia (Recurrent, Treatment-resistant) in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Haematological-malignancies in France (Parenteral)
  • 27 May 2015 Pharmacodynamics data from a preclinical trial is Haematological malignancies released by MacroGenics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top